Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023.
ESMO 2023: Updates in Non-Small Cell Lung Cancer (NSCLC)
An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.
Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023.
An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.
Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.
Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Culturally Competent Menopause Care: Lisa Taylor-Swanson, PhD
3
Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC
4
Age-Related Disparities in ADC Treatment Rates in Breast Cancer with Tabby Khan, MD
5
